Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) ...

MBOT moves to full U.S. launch of its LIBERTY robotic system after strong hospital adoption, boosting momentum for faster market uptake and sales growth.

Microbot Medical (Nasdaq:MBOT) today announced the full market release of its Liberty endovascular surgical robot in the U.S.

Microbot Medical Inc. announces a direct offering of common stock and a concurrent private placement, raising approximately $13 million. Microbot Medical Inc. announced a registered direct offering ...

Microbot Medical Inc. has appointed Ms. Michal Ahuvia as the new Director of Operations to enhance production and efficiency ahead of the commercial launch of their LIBERTY® Endovascular Robotic ...

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company ...

Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the ...

HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of ...

Microbot Medical ( (MBOT)) has issued an announcement. Microbot Medical Inc. has amended and is utilizing its existing at-the-market equity offering program with H.C. Wainwright & Co., allowing it to ...

HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE)-- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it will ...

View Microbot Medical Inc MBOT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...